학술논문

Laboratory monitoring of patients with hereditary tyrosinemia type I.
Document Type
Article
Source
Molecular Genetics & Metabolism. Aug2020, Vol. 130 Issue 4, p247-254. 8p.
Subject
*PATIENT monitoring
*METHIONINE
*TANDEM mass spectrometry
*BIOMARKERS
*NEWBORN screening
*AMINO acids
Language
ISSN
1096-7192
Abstract
The prognosis of patients with Hereditary Tyrosinemia Type 1 (HT-1) has greatly improved with early detection through newborn screening and the introduction of nitisinone (NTBC) therapy. A recent guideline calls for periodic monitoring of biochemical markers and NTBC levels to tailor treatment; however, this is currently only achieved through a combination of clinical laboratory tests. We developed a multiplexed assay measuring relevant amino acids, succinylacetone (SUAC), and NTBC in dried blood spots (DBS) to facilitate treatment monitoring. Tyrosine, phenylalanine, methionine, NTBC and SUAC were eluted from DBS with methanol containing internal standards for each analyte and analyzed by liquid chromatography tandem mass spectrometry over 6.5 min in the multiple reaction monitoring positive mode. Pre-analytical and analytical factors were studied and demonstrated a reliable assay. Chromatography resolved an unknown substance that falsely elevates SUAC concentrations and was present in all samples. To establish control and disease ranges, the method was applied to DBS collected from controls (n = 284) and affected patients before (n = 2) and after initiation of treatment (n = 29). In the treated patients SUAC concentrations were within the normal range over a wide range of NTBC levels. This assay enables combined, accurate measurement of revelevant metabolites and NTBC in order to simplify treatment monitoring of patients with HT-1. In addition, the use of DBS allows for specimen collection at home to facilitate more standardization in relation to drug and dietary treatment. • A clinical assay was developed that measures succinylacetone, relevant amino acids and Nitisinone in dried blood spots and is amenable to home collection for the monitoring of patients with Tyrosinemia Type I. • A wide range of NTBC blood levels are effective at controlling succinylacetone concentrations suggesting lower NTBC doses could suppress succinylacetone production. • An interfering substance for succinylacetone was identified which is resolved by LC-MSMS. [ABSTRACT FROM AUTHOR]